BENZPHETAMINE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BENZPHETAMINE HYDROCHLORIDE (BENZPHETAMINE HYDROCHLORIDE).
Benzphetamine is a sympathomimetic amine that acts as a central nervous system stimulant. It primarily works by promoting the release of norepinephrine and dopamine from presynaptic nerve terminals in the brain, which leads to appetite suppression and increased energy expenditure.
| Metabolism | Primarily hepatic via multiple metabolic pathways including N-demethylation and aromatic hydroxylation. The major metabolic enzymes are CYP3A4 and CYP2D6. |
| Excretion | Primarily renal (approximately 70-90% of the dose excreted unchanged in urine, with the remainder as metabolites including amphetamine and methamphetamine). Fecal excretion is minimal (<5%). |
| Half-life | Benzphetamine has a long elimination half-life of 10-16 hours (up to 20 hours in some individuals). Its active metabolites (amphetamine and methamphetamine) have half-lives of 10-12 hours and 9-11 hours, respectively. Steady state is reached within 3-4 days. The long half-life supports once-daily dosing but carries risk of accumulation with renal impairment. |
| Protein binding | Binding to plasma proteins (primarily albumin) is approximately 20-30%, which is relatively low and unaffected by renal or hepatic disease. |
| Volume of Distribution | Apparent Vd is 3-5 L/kg, indicating extensive tissue distribution. High lipid solubility allows penetration into the central nervous system. |
| Bioavailability | Oral bioavailability is high (estimated >80%) based on rapid absorption and low first-pass metabolism. Food may delay absorption but does not reduce total bioavailability. |
| Onset of Action | Oral: Onset of appetite suppression occurs within 30-60 minutes after ingestion; peak anorectic effect is seen at 2-4 hours. |
| Duration of Action | Anorectic effect persists for 6-10 hours after a single oral dose, though central nervous system stimulation may last longer (12-14 hours). Due to active metabolites, residual effects can extend up to 24 hours. Tolerance to appetite suppression develops over 3-6 weeks. |
25-50 mg orally once daily, may increase by 25 mg increments at weekly intervals; maximum 100 mg/day.
| Dosage form | TABLET |
| Renal impairment | eGFR <30 mL/min: contraindicated; eGFR 30-59 mL/min: use with caution, consider 50% dose reduction. |
| Liver impairment | Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated. |
| Pediatric use | Children ≥6 years: initial 5-10 mg orally once daily; maximum 30 mg/day; weight-based: 0.2-0.5 mg/kg/day. |
| Geriatric use | Initial 5-10 mg orally once daily; caution due to increased cardiovascular risk and lower clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BENZPHETAMINE HYDROCHLORIDE (BENZPHETAMINE HYDROCHLORIDE).
| Breastfeeding | Benzphetamine hydrochloride is excreted into human breast milk. The milk-to-plasma ratio is unknown but is expected to be similar to other amphetamines (approximately 1.0). Breastfeeding infants may experience irritability, poor feeding, and insomnia. Due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | Benzphetamine hydrochloride is classified as FDA Pregnancy Category X. Studies in animals and humans have demonstrated fetal abnormalities, and there is evidence of human fetal risk based on adverse reaction data from investigational or marketing experience. Use is contraindicated in women who are or may become pregnant. First trimester exposure is associated with increased risk of major congenital malformations, particularly cardiovascular and central nervous system defects. Second and third trimester exposure may lead to fetal growth restriction, prematurity, and neonatal withdrawal symptoms including tachycardia, irritability, and poor feeding. |
■ FDA Black Box Warning
Benzphetamine has a high potential for abuse and dependence. It should be used only in patients with exogenous obesity and as part of a comprehensive weight reduction program. Misuse may cause serious cardiovascular events or death.
| Serious Effects |
["History of drug abuse or dependence","Advanced arteriosclerosis","Symptomatic cardiovascular disease","Moderate to severe hypertension","Hyperthyroidism","Hypersensitivity to sympathomimetic amines","Glaucoma","Agitated states","History of seizures","Monoamine oxidase inhibitor (MAOI) use within 14 days","Pregnancy or lactation"]
| Precautions | ["May cause dependence and tolerance; use with caution in patients with a history of drug abuse.","May increase blood pressure and heart rate; monitor cardiovascular status.","Risk of pulmonary hypertension and valvular heart disease with chronic use.","May exacerbate psychiatric disorders; use with caution in patients with bipolar disorder or psychosis.","May impair ability to drive or operate heavy machinery.","Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or anxiety disorders."] |
| Food/Dietary |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight regularly. Assess for signs of stimulant abuse or dependence. Fetal monitoring includes serial ultrasound assessments for growth restriction and amniotic fluid volume. Neonates should be monitored for withdrawal symptoms such as tachycardia, jitteriness, and feeding difficulties for the first 48 hours after delivery. |
| Fertility Effects | Benzphetamine may impair fertility in females by disrupting normal hormonal cycles and causing anovulation due to its sympathomimetic effects. In males, it may reduce sperm count and motility. These effects are generally reversible upon discontinuation. |
| Avoid excessive caffeine intake (coffee, tea, cola, energy drinks) as it may increase stimulant effects. No specific food restrictions; however, a calorie-restricted diet is essential for weight loss. Do not consume alcohol while taking benzphetamine. |
| Clinical Pearls | Benzphetamine is a sympathomimetic amine indicated for short-term (up to 12 weeks) adjunctive therapy for exogenous obesity. Monitor for tachyphylaxis; if tolerance develops, discontinue use. Avoid in patients with a history of substance abuse, cardiovascular disease, hyperthyroidism, glaucoma, or during/within 14 days of MAO inhibitor therapy. Use with caution in patients on antihypertensive agents, as it may reduce their efficacy. Assess for potential drug abuse and dependence; schedule III controlled substance. |
| Patient Advice | Take benzphetamine exactly as prescribed; do not increase dose or frequency without consulting your doctor. · Do not take this medication late in the day to prevent insomnia. · Report any chest pain, palpitations, shortness of breath, or leg swelling immediately. · Avoid alcohol and other CNS stimulants while taking this medication. · Inform your doctor if you have a history of heart disease, high blood pressure, glaucoma, hyperthyroidism, or substance abuse. · Do not use this medication if you are pregnant, planning to become pregnant, or breastfeeding. · Store at room temperature away from moisture and heat, and keep out of reach of children. · Do not stop taking benzphetamine abruptly without consulting your doctor. |